Cure Today22 小时
P1101 Treatment Meets Phase 3 Primary End Point in Essential Thrombocythemia
P1101 had durable hematologic responses and manageable safety among patients with essential thrombocythemia, meeting the ...
Cure Today3 小时
A Breakdown of Trial Data that Led to the Subcutaneous Opdivo FDA Approval
Dr. Eric K. Singhi discusses the significance of the FDA approval of subcutaneous Opdivo for patients with solid tumors.
Cure Today20 小时
The Impact of Yescarta on Long Term Quality of Life in R/R Follicular Lymphoma
Dr. Sattva S. Neelapu discusses how the CAR-T therapy Yescarta impacts the quality of life of patients with R/R indolent non-Hodgkin lymphoma.